Stratifin (SFN) is an adapter protein that regulates diverse signaling pathways by binding to phosphorylated serine and threonine residues on target proteins, modulating their activity. A central function involves maintaining epithelial cell adhesion through interaction with PKP3, which it sequesters to the cytoplasm to preserve desmosome junction integrity and promote keratinocyte intercellular adhesion. Additionally, SFN inhibits innate immune responses by retaining the GBP1 GTPase in the cytosol and acts as a p53-regulated inhibitor of G2/M cell cycle progression. SFN is upregulated in multiple human cancers, including ovarian and hepatocellular carcinoma (HCC), where elevated expression correlates with worse prognosis 1. In HCC, SFN promotes malignant progression by hyperactivating AKT signaling through disruption of PHLPP2-AKT binding, with SFN overexpression reducing responsiveness to sorafenib 2. The compound sulforaphane, derived from cruciferous vegetables and known to interact with cellular targets through cysteine modification, has shown potential therapeutic applications in cancer immunotherapy and inflammatory diseases, though its relationship to the protein stratifin remains mechanistically distinct.